Smallpox Vaccination Adverse Reactions: Clinical Guidance for Pre-Outbreak Settings

Clinical guidance for evaluating and treating patients with complications from smallpox vaccination in a pre-outbreak setting. The report includes information on adverse event frequencies identified in 1960s studies, contraindications, and available therapies like vaccinia immune globulin (VIG) and cidofovir. It was authored by Joanne Cono of the Office of Readiness and Response.

Use Cases

• Training clinical decision support systems based on described contraindications and treatment protocols.
• Informing public health policy on vaccination safety based on historical adverse event frequencies from the 1960s.
• Developing patient education materials based on described transmission risks and post-vaccination care instructions.

Strengths

• Provides specific contraindications for vaccination, including conditions like atopic dermatitis and immunocompromised states.
• Details first-line (vaccinia immune globulin) and second-line (cidofovir) therapies for severe adverse reactions.
• Includes guidance on preventing transmission of the vaccinia virus from vaccinees to contacts.

Limitations

• Adverse reaction rates are based on studies from the 1960s, and precise predictions for today's population are unavailable.
• Row count and column-level documentation are unknown, limiting suitability assessment for structured data analysis.
• Last update date is unknown; freshness unverified.

Provenance

Source

Joanne Cono, Office of Readiness and Response

Collection Method

Guidance document compiling clinical information and historical studies.